172 related articles for article (PubMed ID: 30821899)
41. Farnesoid X Receptor Agonist Represses Cytochrome P450 2D6 Expression by Upregulating Small Heterodimer Partner.
Pan X; Lee YK; Jeong H
Drug Metab Dispos; 2015 Jul; 43(7):1002-7. PubMed ID: 25926433
[TBL] [Abstract][Full Text] [Related]
42. Association study between functional polymorphisms in the cytochrome P450 1A2 and 2D6 genes and polydipsia in schizophrenia.
Matsumoto C; Shinkai T; De Luca V; Hori H; Hwang R; Ohmori O; Kennedy JL; Nakamura J
Neuromolecular Med; 2006; 8(3):381-8. PubMed ID: 16775389
[TBL] [Abstract][Full Text] [Related]
43. Effectiveness of a high-throughput genetic analysis in the identification of responders/non-responders to CYP2D6-metabolized drugs.
Savino M; Seripa D; Gallo AP; Garrubba M; D'Onofrio G; Bizzarro A; Paroni G; Paris F; Mecocci P; Masullo C; Pilotto A; Santini SA
Clin Lab; 2011; 57(11-12):887-93. PubMed ID: 22239018
[TBL] [Abstract][Full Text] [Related]
44. CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits.
Dorado P; Peñas-Lledó EM; Llerena A
Pharmacogenomics; 2007 Nov; 8(11):1597-608. PubMed ID: 18034624
[TBL] [Abstract][Full Text] [Related]
45. Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates.
Yu AM; Idle JR; Gonzalez FJ
Drug Metab Rev; 2004 May; 36(2):243-77. PubMed ID: 15237854
[TBL] [Abstract][Full Text] [Related]
46. Increased prevalence of functional minor allele variants of drug metabolizing CYP2B6 and CYP2D6 genes in Roma population samples.
Weber A; Szalai R; Sipeky C; Magyari L; Melegh M; Jaromi L; Matyas P; Duga B; Kovesdi E; Hadzsiev K; Melegh B
Pharmacol Rep; 2015 Jun; 67(3):460-4. PubMed ID: 25933954
[TBL] [Abstract][Full Text] [Related]
47. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.
Lim KS; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Cho JY; Shin SG; Yu KS
Clin Ther; 2010 Apr; 32(4):659-66. PubMed ID: 20435235
[TBL] [Abstract][Full Text] [Related]
48. Determination of CYP2D6 gene copy number by multiplex polymerase chain reaction analysis.
Leandro-García LJ; Leskelä S; Montero-Conde C; Landa I; López-Jimenez E; Letón R; Seeringer A; Kirchheiner J; Cascón A; Robledo M; Rodríguez-Antona C
Anal Biochem; 2009 Jun; 389(1):74-6. PubMed ID: 19303860
[TBL] [Abstract][Full Text] [Related]
49. [Polymorphisms in the genes of cytochrome oxidase P450 2D6 (CYP2D6), paraoxonase 1 (PON1) and apolipoprotein E (APOE) as risk factors for Parkinson's disease].
Durić G; Svetel M; Nikolaevic SI; Dragadević N; Gavrilović J; Kostić VS
Vojnosanit Pregl; 2007 Jan; 64(1):25-30. PubMed ID: 17304721
[TBL] [Abstract][Full Text] [Related]
50. Transcriptional Regulation of CYP2D6 Expression.
Pan X; Ning M; Jeong H
Drug Metab Dispos; 2017 Jan; 45(1):42-48. PubMed ID: 27698228
[TBL] [Abstract][Full Text] [Related]
51. Effect of genetic polymorphism on the inhibition of dopamine formation from p-tyramine catalyzed by brain cytochrome P450 2D6.
Niwa T; Shizuku M; Yamano K
Arch Biochem Biophys; 2017 Apr; 620():23-27. PubMed ID: 28347660
[TBL] [Abstract][Full Text] [Related]
52. In-vitro cytochrome P450 dependent metabolism of oxybutynin to N-deethyloxybutynin in humans.
Yaïch M; Popon M; Médard Y; Aigrain EJ
Pharmacogenetics; 1998 Oct; 8(5):449-51. PubMed ID: 9825837
[TBL] [Abstract][Full Text] [Related]
53. Gene expression of cytochrome P450 1B1 and 2D6 in leukocytes in human pregnancy.
Lind AB; Wadelius M; Darj E; Finnström N; Lundgren S; Rane A
Pharmacol Toxicol; 2003 Jun; 92(6):295-9. PubMed ID: 12787262
[TBL] [Abstract][Full Text] [Related]
54. Human liver enzymes responsible for metabolic elimination of tyramine; a vasopressor agent from daily food.
Niwa T; Murayama N; Umeyama H; Shimizu M; Yamazaki H
Drug Metab Lett; 2011 Aug; 5(3):216-9. PubMed ID: 21679153
[TBL] [Abstract][Full Text] [Related]
55. Potential role of CYP2D6 in the central nervous system.
Cheng J; Zhen Y; Miksys S; Beyoğlu D; Krausz KW; Tyndale RF; Yu A; Idle JR; Gonzalez FJ
Xenobiotica; 2013 Nov; 43(11):973-84. PubMed ID: 23614566
[TBL] [Abstract][Full Text] [Related]
56. Nrf2 Regulates the Expression of
Siswanto FM; Handayani MDN; Firmasyah RD; Oguro A; Imaoka S
Curr Drug Metab; 2023; 24(9):667-681. PubMed ID: 37916628
[TBL] [Abstract][Full Text] [Related]
57. Effect of Cytochrome P450 (CYP) 2D6 Genetic Polymorphism on the Inhibitory Action of Antidepressants on CYP2D6-Mediated Dopamine Formation from p-Tyramine.
Niwa T; Yanai M; Matsumoto M; Shizuku M
J Pharm Pharm Sci; 2018; 21(1):135-142. PubMed ID: 29602316
[TBL] [Abstract][Full Text] [Related]
58. Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development.
Zhou SF; Liu JP; Lai XS
Curr Med Chem; 2009; 16(21):2661-805. PubMed ID: 19601803
[TBL] [Abstract][Full Text] [Related]
59. [Relation between cytochrome P450 2D6 and lung cancer susceptibility caused by smoking].
Yan Z; Wu Y; Wu Y
Wei Sheng Yan Jiu; 2007 Jan; 36(1):112-3, 116. PubMed ID: 17424863
[TBL] [Abstract][Full Text] [Related]
60. Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics.
Shen HW; Wu C; Jiang XL; Yu AM
Biochem Pharmacol; 2010 Jul; 80(1):122-8. PubMed ID: 20206139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
